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PRECLINICAL RESEARCH
mproved Graft Mesenchymal Stem
ell Survival in Ischemic Heart With
Hypoxia-Regulated Heme Oxygenase-1 Vector
ao Liang Tang, MD, PHD,* Yi Tang, MD, PHD,§ Y. Clare Zhang, PHD,†‡ Keping Qian, PHD,†‡
eping Shen, MS,†‡ M. Ian Phillips, PHD, DSC*
t. Petersburg, Florida; and Stanford, California
OBJECTIVES The goal of this study was to modify mesenchymal stem cells (MSCs) cells with a
hypoxia-regulated heme oxygenase-1 (HO-1) plasmid to enhance the survival of MSCs in
acute myocardial infarction (MI) heart.
BACKGROUND Although stem cells are being tested clinically for cardiac repair, graft cells die in the ischemic
heart because of the effects of hypoxia/reoxygenation, inflammatory cytokines, and proapop-
totic factors. Heme oxygenase-1 is a key component in inhibiting most of these factors.
METHODS Mesenchymal stem cells from bone marrow were transfected with either HO-1 or LacZ plasmids.
Cell apoptosis was assayed in vitro after hypoxia-reoxygen treatment. In vivo, 1  106 of male
MSCHO-1, MSCLacZ, MSCs, or medium was injected into mouse hearts 1 h after MI (n 
16/group). Cell survival was assessed in a gender-mismatched transplantation model. Apoptosis,
left ventricular remodeling, and cardiac function were tested in a gender-matched model.
RESULTS In the ischemic myocardium, the MSCHO-1 group had greater expression of HO-1 and a
2-fold reduction in the number of terminal deoxynucleotidyl transferase-mediated deoxyuri-
dine triphosphate in situ nick end labeling-positive cells compared with the MSCLacZ group.
At seven days after implantation, the survival MSCHO-1 was five-fold greater than the
MSCLacZ group; MSCHO-1 also attenuated left ventricular remodeling and enhanced the
functional recovery of infarcted hearts two weeks after MI.
CONCLUSIONS A hypoxia-regulated HO-1 vector modification of MSCs enhances the tolerance of engrafted
MSCs to hypoxia-reoxygen injury in vitro and improves their viability in ischemic hearts.
This demonstration is the first showing that a physiologically inducible vector expressing of
HO-1 genes improves the survival of stem cells in myocardial ischemia. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.0792005;46:1339–50) © 2005 by the American College of Cardiology Foundation
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Tleading cause of heart failure is myocardial ischemia, which
recipitates dysfunction and the death of cardiomyocytes (1).
dult stem cells have been proposed as a promising source for
he repair and regeneration of heart cells and for the restoration
See page 1351
f heart function (2–4). However, progress in stem cell therapy
s hampered by the poor survival of implanted cells. A high
evel of engrafted cell death occurs within four days after
rafting into injured hearts (5,6). Furthermore, regenerated
issue from stem cells does not survive repeated bouts of
schemia (7). The molecular mechanism for stem cell death in
schemic heart is in large part because of ischemia; moreover,
ndogenous and environmental factors, such as ischemia-
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niversity of South Florida, St. Petersburg, Florida; and §Department of Surgery,
niversity of Stanford, Stanford, California. Dr. Yao Liang Tang is recipient of
ostdoctoral fellowship from American Heart Association (0325378B). Dr. Phillips is
upported by grants from the National institutes of Health HL 77602, MERIT
L27339. Dr. Yi Tang is recipient of predoctoral fellowship from American Heart
ssociation (0110140B).s
Manuscript received December 27, 2004; revised manuscript received April 9,
005, accepted May 17, 2005.eperfusion, inflammatory response, and proapoptotic factors,
lay important roles. Therefore, cytoprotection for one week is
ritical for improving the efficiency of cell therapy.
We have developed a hypoxia-inducible vector system
hat can induce transgene expression in response to hypoxia
n the heart without the need for exogenous stimuli, such as
rugs (8–11). Heme oxygenase-1 (HO-1), an antiapoptotic
nd antioxidant enzyme, possesses potent cytoprotective
ctivity in an ischemic environment (12,13). To develop a
trategy aimed at enhancing stem cell viability in the
hort-term and at enhancing stem cell resistance to isch-
mia, we transfected mesenchymal stem cells (MSCs) with
he hypoxia-regulated system and hypothesized that HO-1
ould be switched automatically on by hypoxia and confer
imely cellular protection to MSCs in danger. We proposed
hat gene modification of stem cells with hypoxia-inducible
O-1 vector would improve stem cell viability and thereby
otentially improve stem cell therapy for heart disease.
ETHODS
eneration of hypoxia-inducible human HO-1 plasmid.
he hypoxia-inducible plasmid system is a double-plasmidystem (Fig. 1) containing a sensor plasmid with the
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Hypoxia-Inducible Vector Salvage Graft Cells October 4, 2005:1339–50xygen-sensitive toggle (OST) and an effector plasmid with
he cardiac protective gene (8–10). The sensor plasmid
pS-OST) contains an oxygen-dependent degradation do-
ain (amino acids 394 to 603). This domain was amplified
y polymerase chain reaction (PCR) from pCEP4/HIF-
-alpha and inserted in the frame between the coding
equence of GAL4DNA binding domain and p65 acti-
ation domain in pS-CMV to generate pS-OST (Fig. 1).
he effector plasmid (pE-hHO-1) was constructed by
eplacing the LacZ coding sequence with full-length
DNA for human heme oxygenase-1 (hHO-1) in pE/
5-His/LacZ (Invitrogen Corporation, Carlsbad, Cali-
ornia). A six-copy His tag was added to the C-terminal
f hHO-1. Human HO-1 is driven by six copies of a
7-bp GAL4 UAS and an adenovirus-derived E1b
ATA box. The construction of the plasmids was con-
rmed by nucleotide sequence analysis.
nimals. All studies were performed with the approval of
he University of South Florida Institutional Animal Care
nd Use Committee. The investigation conformed to the
rinciples of Laboratory Animal Care formulated by the
ational Society for Medical Research and the Guide for
he Care and Use of Laboratory Animals published by the
.S. National Institutes of Health. The syngenic male and
emale mouse strain BAL B/c (Harlan) weighing 20 to 25 g
as used to avoid rejection.
ell isolation, culture, transfection, and labeling. Bone
arrow was flushed from tibias and femurs of male donor
ice using a 25-gauge needle. Whole marrow cells were
ultured at 1  106/cm2 in MesenCult basal medium that
as supplemented with MSC stimulatory supplements
StemCell Technologies Inc., Vancouver, BC, Canada).
he nonadherent cells were removed by a medium change
t 72 h and every four days thereafter. The monolayer,
eferred to as MSCs, was expanded by two passages.
A Polyethylenimine-Transferinfection Kit (Tf PEI-Kit;
ender MedSystems, Burlingame, California) was prepared
ccording to commercial protocol. Briefly, two plasmids
1:1) were mixed with a Tf PEI to generate a Tf PEI/DNA
Abbreviations and Acronyms
cTNT  cardiac troponin T
DAPI  4=,6-diamidino-2=-phenylindole
FITC  fluorescein isothiocyanate
HO-1  heme oxygenase-1
IL  interleukin
LV  left ventricular
MI  myocardial infarction
MSC  mesenchymal stem cell
OST  oxygen-sensitive toggle
PCR  polymerase chain reaction
TRITC  tetramethyl rhodamine isothiocyanate
TUNEL  terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate
in situ nick end labelingomplex suspension. Mesenchymal stem cells at 70% con-
h
ruence were incubated with the Tf PEI/DNA containing
he sensor plasmid and effector plasmid for 4 h at 37°C.
ontrol cells were transfected with inducible vector with
acZ as reporter using the same protocol.
Before implantation, MSCs were trypsinized, washed,
nd labeled with 4=,6-diamidino-2=-phenylindole (DAPI)
Sigma, St. Louis, Missouri), as previously described (14).
n brief, sterile DAPI stock solution was added to culture
edium at a final concentration of 50 g/ml for 30 min.
fter labeling, cells were washed six times in D-Hanks
olution to remove excess unbound DAPI. The DAPI stains
ere 100% of the MSCs nuclei.
n vitro experiments. HYPOXIA PROTOCOL AND REPORTER
ENE EXPRESSION. To evaluate hypoxia regulation of
ypoxia-inducible hHO-1 vectors and hypoxia-inducible
acZ in vitro, cells were incubated on eight-well Lab-
ek Chamber Slides (Nalge Nunc International, Roch-
ster, New York). Cell transfection and hypoxic treat-
ent was performed as described previously (8).
esenchymal stem cells were transfected with 1 g of
S-OST and 0.5 g of pE-hHO-1/pE-LacZ. Twenty-
our hours after transfection, the medium was changed
nd MSCs were incubated at 1% or 20% O2 for 24 h
efore the preparation of lysates. Each condition was run
n triplicate.
LacZ expression was assayed using “LacZ Cell Staining
it” according to the manufacturer’s protocol (InvivoGen,
an Diego, California). For immunofluorescent examina-
ion of hHO-1, samples were incubated in a 1:50 dilution of
ntihuman HO-1 antibody at 37°C for 30 min, followed by
ncubation in a 1:500 dilution of fluorescein isothiocyanate
FITC)-conjugated second antibody (Sigma).
Western blot analysis was performed using 10 to 15 g of
hole cell. The hHO-1-6xHis fusion protein was probed
ith monoclonal anti-6xHis antibody (Invitrogen). The
nternal control proteinglyseraldehyde-3-phosphate dehy-
igure 1. Diagram of hypoxia-regulated plasmid system, which can am-
lify the power of a promoter based on the strong transcription activity of
he GAL4/p65 fusion protein. The ischemic biosensor is composed of an
xygen-sensing toggle (OST), which is a GAL4DNA-binding domain,
DD of the hypoxia-inducible factor-1-alpha along with p65 activation
omain. The effector plasmid contains GAL4 upstream activation se-
uence (UAS) in front of an adenovirus E1b TATA box and the
HO-1-6xHis or LacZ fusion gene. Hypoxia inducible LacZ system is
eplaced hHO-1 gene with LacZ.
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fornia) was probed. The antigen-antibody complexes were
isualized by enhanced chemiluminescence (Amershan plc,
uckinghamshire, United Kingdom).
YPOXIA-REOXYGEN PROTOCOL. To test the capability of
esistance to ischemia/reperfusion damage of MSCs, we
sed hypoxia/reoxygen/hypoxia treatment on MSCHO-1,
SCLacZ, and MSCs with 24 h of hypoxia (1% O2), 1 h of
eoxygen (20% O2), followed by another 24 h of hypoxia.
ETECTIONOF APOPTOSIS CAUSED BY HYPOXIA/REOXYGEN
NJURY. For detection of the proapoptosis protein Bax,
onoclonal anti-Bax antibody (Upstate Biotechnology,
harlottesville, Virginia) was used in Western blot. For
mmunofluorescent analysis, MSCs were seeded into cham-
er slides at day 2 after transfection for hypoxia-reoxygen
reatment. After that, samples were fixed with 4% formal-
ehyde. Half samples were incubated in a 1:50 dilution of
ntihuman HO-1 antibody at 37°C for 30 min, followed by
ncubation in a 1:500 dilution of tetramethyl rhodamine
sothiocyanate (TRITC)-conjugated secondary antibody
Sigma). For the other samples, we used the terminal
eoxynucleotidyl transferase-mediated deoxyuridine
riphosphate in situ nick end labeling (TUNEL) assay
ccording to manufacturer’s protocol (Upstate). Nuclei were
ounterstained with DAPI. The degree of apoptosis is
alculated as the number of TUNEL cells per 500 nuclear
umbers of MSCs.
n vivo experiments. MYOCARDIAL INFARCTION (MI)
ODEL AND CELL IMPLANTATION. Male BAL B/c mice
ere anesthetized with sodium pentobarbital (40 mg/kg,
.p.) and mechanically ventilated. The sham operation was
ade by passing suture around the left coronary artery
ithout ligation. After the heart was exposed through a
ateral thoracotomy, an 8-0 polypropylene thread was passed
round the left coronary artery and the artery was occluded.
t day 3 after gene transfection, MSCs were harvested
sing trypsin and resuspended in serum-free Dulbecco’s
odified Eagle’s medium just before grafting to the heart.
he male MSCs were used for the following three-part
xperiments: 1) Gender-mismatched transplants for quan-
ifying survival MSCs by real-time PCR: 1.2  106 of
HO-1- transfected-male MSCs (MSCHO-1) and LacZ-
ransfected male MSCs (MSCLacZ group) in 50 l of
olume were injected into syngenic female BAL B/c mouse
earts 1 h after MI with a 30-gauge needle (n  16/group).
) Gender-matched transplants for remodeling and func-
ional comparison: 1 106 of MSCHO-1, MSCLacZ, MSCs,
r medium (n 16/group) in 50 l of volume were injected
nto male BAL B/c mouse hearts 1 h after MI. 3) To test
he role of HO-1 in preventing inflammation, a group of
I mice were injected intramyocardially with hypoxia-
egulated hHO-1 or LacZ plasmid (n 10/group) 1 h afterI as described previously (15). iEAL-TIME PCR. Genomic DNA was isolated using
enomic-tip Kit (Qiagen, Amsterdam, the Netherlands).
eal-time PCR was conducted as described elsewhere (16)
n a 5700 sequence detection system (Applied Biosystems
roup, Foster City, California). Standard curves were
enerated by serially diluting murine male genomic DNA
repared from male MSCs. The sequence of the PCR
rimers and probe used for detection of murine male-
pecific Sry gene were as follows (17):
orward primer: 5=-GGAGAGAGGCACAAGTTGGC-3=;
everse primer: 5=-TTCCAGCTGCTTGCTGATC-3=
aqman probe: 5=-FAM-CAACAGAATCCCAGCATG
CAGAATTCAG-TAMRA-3=
The measurement of Sry genes in MSCHO-1- and
SCLacZ-grafted hearts was conducted at 4 h (n 
/group), 24 h (n  3/group), and 7 days (n  3/group)
fter gender-mismatch transplants.
SSAY FOR THE INFLAMMATORY RESPONSE IN PLASMID-
REATED HEARTS. Western blot analysis was performed
sing 125 g of protein from HO-1- and LacZ plasmid-
reated hearts one day after injection (n  3/group). The
nterleukin (IL)-1 protein was probed with monoclonal
nti–IL-1 antibody (Invitrogen). The internal control
rotein GAPDH antibody was probed. The ratio of IL-1:
APDH was compared between two group using Quantity
ne software (Bio-Rad, Hercules, California). Immuno-
taining for CD45 was performed four days after plasmid
njection, and the tissue sections were fixed in 4% formal-
ehyde for 10 min. Sections of HO-1- and LacZ plasmid-
reated hearts were incubated with a 1:50 dilution of
iotin-conjugated rat anti-mouse CD45 antibody (BD
ioscience, San Jose, California) using DakoCytomation
he ARK (Animal Research Kit) (DakoCytomation,
arpinteria, California).
SSAY FOR REPORTER GENE EXPRESSION IN GRAFTED
ELLS AT ISCHEMIA. Three hearts from MSCHO-1- and
SCLacZ-engrafted hearts were embedded in Tissue-Tek
CT (Sakura Finetek U.S.A. Inc., Torrence, California) at
our days after implantation, 5-m cryostat sections were
btained in MSCHO-1 tissue, whereas three adjacent sec-
ions with 5-, 20-, and 5-m sequence were cut in
SCLacZ. The sections of MSCHO-1 and MSCLacZ were
ncubated with a 1:50 dilution of antihuman HO-1 anti-
ody followed by incubation in a 1:500 dilution of TRITC-
onjugated secondary antibody. To identify LacZ expres-
ion in ischemic myocardium, a 20-m section of MSCLacZ
eart was stained using the LacZ Tissue Staining Kit
ccording to manufacturer’s protocol (InvivoGen).
UNCTIONAL ASSESSMENT. At 14 days after cell trans-
lantation, mice from gender-match transplant groups
nd sham group (n  6 in each group) were performed
nvasive left ventricular (LV) hemodynamic measurement
n closed-chest preparation as described (18). Mice were
a
T
l
i
L
a
m
s
i
c
R
t
a
l
(
M
i
i
m
p
T
t
I
f
p
B
p
T
b
c
t
a
d
a
L
1
a
o
u
S
S
i
S
m
0
p
M
t
p
R
H
s
s
O
s
c
4
h
c
b
M
n
w
p
r
r
i
r
M
n
M
a
r
M
p

b
r
o
w
H
c
t
e
c
h
c
h
n
t
k
h
i
h
i
I
c
d
i
g
t
T
0
M
M
i
i
1342 Tang et al. JACC Vol. 46, No. 7, 2005
Hypoxia-Inducible Vector Salvage Graft Cells October 4, 2005:1339–50nesthetized by pentobarbital (40 mg/kg, i.p.). Mikro-
ip pressure catheter transducers (Model SPR-671, Mil-
ar Instruments Inc., Houston, Texas) were cannulated
nto the LV chamber through right carotid artery. The
V pressure was digitized using the commercially avail-
ble data acquisition system (PowerLab/8sp, ADinstru-
ents Inc., Mountain View, California). After steady
tate had been established, maximal rates of pressure
ncrease and decrease (dP/dt) were recorded in the
losed-chest preparation.
EMODELING, APOPTOSIS, AND CELL DIFFERENTIATION. Af-
er invasive LV functional detection, mice were killed with
n overdose of pentobarbital. Hearts at the papillary muscle
evel were selected and embedded in Tissue-Tek OCT
Sakura). Cryostat sections (5 m each) were obtained in
SCHO-1, MSCLacZ, MSCs, and medium for Masson stain-
ng and immunofluorescent staining. Masson trichrome stain-
ng was performed using a commercial kit according to
anufacturer’s protocol (Sigma). Sections from all slices were
rojected onto a screen for computer-assisted planimetry.
he percentage of fibrotic area in a total LV area and the
hickness of infarct wall were assayed by analySIS (Soft
maging System GmbH, Lakewood, Colorado). We per-
ormed the TUNEL assay according to the manufacturer’s
rotocol. Sections were counterstained with Eriochrome
lue-Black R (LabChem, Pittsburgh, Pennsylvania). The
ercentage of apoptosis is calculated as the number of
UNEL-positive cell number/DAPI-labeled nuclear num-
ers of MSCs  100. An average of 200 cells per slide was
ounted. The slices from MSCHO-1 also were used to assay
he alpha-sarcomeric actinin, cardiac troponin T (cTnT),
nd CD31 expression. The sections were incubated with 1:50
ilution of monoclonal anti–alpha-sarcomeric actin (Sigma)
nd polyclonal anti-cTnT (Advanced Immunochemical,
ong Beach, California) followed by incubation with a
:500 dilution of TRITC-conjugated anti-rabbit antibody
nd FITC-conjugated antimouse antibody. A 1:50 dilution
f FITC conjugated monoclonal anti-CD31 (Sigma) was
sed to identify endothelial cells.
tatistical analysis. All values are expressed as mean 
EM. The Student t test was used for two-group compar-
son and analysis of variance followed by an unpaired
tudent t test with Bonferroni’s correction was used for
ultiple group comparisons. Reported significances (p 
.05, p  0.01) were calculated by Bonferroni-adjusted
airwise comparisons between MSCHO-1 group with the
SCLacZ-treated group, MSC group, or medium group for
he respective parameter (Figs. 2B and 3C to 3F). Values of
 0.05 were considered significant.
ESULTS
uman HO-1 expression protects against MSC apopto-
is in vitro. A total of 80% of LacZ-transfected MSCs
tained positively for beta-Gal after hypoxia treatment (1%2 for 24 h). Immunofluorescent staining demonstrated ltronger hHO-1 expression in hypoxia-treated MSCHO-1
ompared with MSCHO-1 in normoxia (Figs. 4A1 and
A2). Beta-gal staining in vitro showed that there was a
igher level expression of LacZ in MSCLacZ during hypoxia
ompared with normoxia (Figs. 4A3 and 4A4). Western
lotting showed that total hHO-1 levels in hypoxia-treated
SCHO-1 was on average 5.18-fold more abundant than at
ormoxia (p  0.001) (Figs. 4B and 4C). Because hHO-1
as fused with 6xHis tag in the vector, the expressed fusion
rotein reacts only with antibody to 6xHis and does not
eact with endogenous mouse HO-1.
To test the capability of MSCHO-1 to resist ischemia/
eperfusion damage, we applied hypoxia/reoxygen/hypoxia
njury to MSCHO-1 with 24 h of hypoxia (1% O2), 1 h of
eoxygen (20% O2), followed by another 24 h of hypoxia.
ost of MSCHO-1 expressed HO-1 fusion protein in immu-
ostaining whereas HO-1 expression was low in MSCLacZ and
SCs. The increase in HO-1 expression in MSCHO-1 was
ccompanied by a decrease in the MSC apoptosis. As a
esult, the rate of cell apoptosis by TUNEL in MSCLacZ or
SCs (5.06  0.43 TUNEL and 5.32  0.46 TUNEL
er 500 cells, respectively) exceeded that of MSCHO-1 (3.00
0.13 TUNEL per 500 cells) by 1.7-fold (p  0.01 for
oth MSCLacZ and MSCs) (Fig. 5A). Similarly, a down-
egulation in a proapoptotic gene Bax level in the cell lysate
f MSCHO-1 was confirmed by Western blot in comparison
ith MSCLacZ and MSCs (Fig. 5B).
ypoxia-regulated hHO-1 plasmid administration de-
reases inflammatory cytokine levels and leukocyte infil-
ration. After plasmid intramyocardial injection in isch-
mic heart, we found a relative decrease in proinflammatory
ytokines lL-1-beta in ischemic myocardium from the
HO-1–treated hearts compared with the LacZ-treated
ontrols (OD ratio IL-1b/glyseraldehyde-3-phosphate de-
ydrogenase: 0.195  0.046 vs. 0.916  0.246, p  0.045,
 3 hearts/group) (Figs. 6A and 6B). Concomitant with
he reduction in inflammatory factor, CD45-positive leu-
ocyte infiltration was less in the HO-1 plasmid-treated
earts compared with the LacZ-treated hearts in the peri-
nfarct myocardium (Figs. 6C and 6D), indicating that the
HO-1 gene transfer inhibits inflammatory cell infiltration
n ischemic heart.
nduction of human HO-1 expression in ischemic myo-
ardium protects against MSC apoptosis in vivo. At 14
ays after cell injection, the implanted cells were assessed in
schemic myocardium by TUNEL assay. In the MSCHO-1
roup, we observed that a significantly smaller percentage of
he implanted cells were TUNEL positive (2.32  0.39
UNEL per 200) compared with the MSCLacZ (4.98 
.40 TUNEL per 200, p 0.01 vs. MSCHO-1, n 6) and
SCs group (5.54  0.43 TUNEL, p  0.01 vs.
SCHO-1, n  6) (Figs. 2A and 2B). This finding is
nversely correlated with staining four days after plasmid
mplantation, which demonstrated that there was a higher
evel of hHO-1 expression in most of implanted MSCHO-1
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October 4, 2005:1339–50 Hypoxia-Inducible Vector Salvage Graft Cellsells compared with the MSCLacZ (Fig. 2C). Moreover,
onor MSCLacZ was stained positively for LacZ, indicating
schemia-activated LacZ gene in MSCLacZ (Fig. 2D). The
igure 2. Effect of treating mesenchymal stem cells (MSCs) with hypoxia-i
) Quantification of intramyocardial terminal deoxynucleotidyl transferase-
wo weeks after MSC injection. TUNEL-positive implanted cells were sign
p  0.01, n  6/group). (C) Immunofluorescent staining of hHO-1 to de
fter implantation. The number of HO-1-positive graft cell was higher in
onor MSCLacZ stained positively for LacZ marker gene, indicating the iypoxia-regulated HO-1 transfected MSCs did not lose 7heir differentiation capacity in vivo. Some MSCHO-1
tained positively for alpha-sarcomeric actin and cTnT at
eri-infarct area at 14 days after the transplantation (Figs.
ble hHO-1 vector on grafted cell survival in ischemic myocardium. (A and
ated deoxyuridine triphosphate in situ nick end labeling-positive graft cells
tly less in MSCHO-1 group compared with the MSCLacZ and MSCs group
e expression of hypoxia-regulated gene in ischemic myocardium four days
SCHO-1 group than the MSCLacZ groups. (D) At the peri-infarct area,
ia-activated LacZ gene in MSCLacZ. Arrows indicate the -gal nuclei.nduci
medi
ifican
tect th
the MA to 7D). Some labeled MSCHO-1 stained positively for
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Hypoxia-Inducible Vector Salvage Graft Cells October 4, 2005:1339–50igure 3. Injection of mesenchymal stem cells (MSCs) inhibits left ventricular (LV) remodeling and improves LV function. Masson trichrome staining
howed infarct wall was significantly thicker in MSCHO-1 group in compared with other control groups (A and C). The percent of fibrotic area in total
V area was significantly reduced in MSCHO-1 group compared with other control groups (B and D). Left ventricular systolic performance and diastolic
erformance, as assessed by maximum dP/dt and minimum dP/dt, were best in the MSCHO-1 group, indicating that survival MSCHO-1 contribute to
reserve systolic and diastolic functions of infarct heart. Moreover, the MSC and MSCs demonstrated less LV remodeling and better hemodynamicLacZ
unction in comparison with the medium group (E and F).
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October 4, 2005:1339–50 Hypoxia-Inducible Vector Salvage Graft CellsD31 and formed microvessels (Figs. 7E to 7G), indicating
hat survival MSCHO-1 differentiated into cardiomyocytes
nd endothelial cells within the native myocardium.
ypoxia-regulated HO-1 plasmid treatment enhances
SC survival in ischemic myocardium. We quantified
ngraftment levels of male, donor-derived cells in the
schemic hearts of female transplanted recipients using
eal-time PCR. Threshold cycle of the Sry gene in male
SCs have good relation with serially diluted cells (Figs.
A and 8B), R2 0.9879. Real-time PCR assay of Sry gene
uantified the number of survival male MSCs in female
earts treated with MSCHO-1 and MSCLacZ cells. The
urvival ratio  survival MSCs number/ total implanted
ells. Survival ratio was assayed 4 h, 24 h, and 7 days after
igure 4. Hypoxia-induced overexpression of reporter gene in MSCHO-1 and
SCLacZ. (A) Immunostaining for human HO-1 shows that 24 h of hypoxia
ncreased the expression of hHO-1 expression compared with normoxia (1
nd 2). Beta-gal staining in vitro demonstrated that higher level expression of
acZ in hypoxia treated MSCLacZ compared with normoxia (3 and 4). Almost
0% transfected MSCs were positively stained for LacZ after hypoxic
reatment. (B) Western blot demonstrated that the abundances of hHO-1
usion protein were lower in MSCHO-1 at normoxia in comparison with
ypoxia with 6xHis antibody for detection. (C) The hHO-1 fusion protein
evel of MSCHO-1 in hypoxia was 5.18-fold more abundant than in normoxia
mean  SEM; p  0.001; n  3).ransplant, as shown in Figure 8C. The engrafted MSC eurvival was significantly higher in the MSCHO-1 than the
SCLacZ group (4 h: 68.7  6.2% vs. 21.5  9.9%, p 
.016; 24 h: 21.9  3.7% vs. 7.6  1.3%, p  0.022; 7 days:
8.3  4.0% vs. 3.6  1.9%, p  0.029, n  3 hearts/group).
V remodeling and cardiac function after MSCs trans-
lantation. At day 14 after cell transplantation, the thick-
ess of infarct wall was significantly higher in the MSCHO-1
roup compared with the other three groups (Figs. 3A and
C). Furthermore, the percentage of fibrosis area in total
V area was significantly reduced in MSCHO-1-engrafted
ouse heart compared with the other groups (Figs. 3B and
D). Left ventricular systolic performance and diastolic
erformance, as assessed by maximum dP/dt and minimum
P/dt, were significantly better in the MSCHO-1 group
ompared with MSCLacZ, MSCs, and medium group,
ndicating that survival MSCHO-1 contribute to preserve
ystolic and diastolic functions of the infarct heart. The
SCLacZ- and MSC-grafted hearts demonstrated less LV
emodeling and better hemodynamic function in compari-
on with the medium group (Figs. 3E and 3F).
ISCUSSION
e have demonstrated that hypoxia-inducible HO-1 plas-
id modification of MSCs enhances their survival in
schemic myocardium by real-time PCR assay. Moreover,
e showed that the mechanism for enhancing grafted MSC
urvival is related to role of HO-1 in antiapoptosis and
nti-inflammatory in ischemia myocardium. Mesenchymal
tem cells treated with hypoxia-regulated HO-1 plasmid
lso attenuate LV remodeling and improve LV function,
hich is probably due to reduced apoptosis of grafted MSCs
nd reduced apoptosis in the host heart. These data suggest
hat hypoxia-regulated HO-1 plasmid gene modification of
raft stem cells could be of significant value in improving
he effectiveness of cell therapy in ischemic hearts.
The acute donor stem cell death that occurs immediately
fter engraftment is thought to have a major negative impact
n the ensuing graft size and high level of cell death within
our days after grafting into injured hearts (5). To reduce
his attrition, the molecular mechanisms for the grafted cell
eath need to be identified and a graft cell death prevention
trategy devised (19). Multiple mechanisms could contrib-
te to death of graft cells. Recent reports suggest that graft
ells placed in an ischemic environment were dependent on
iffusion for the delivery of oxygen and substrates. In
ddition, host inflammatory response and loss of survival
ignal from cell-cell contact also may contribute to cell death
5). Other reports implicated the role of various proapop-
otic or cytotoxic factors for molecular mechanisms of death
f native or exogenous stem cells in the ischemic hearts (20).
mplanted bone marrow mesenchymal stem cells seem to be
ighly sensitive to hypoxic and inflammatory environment
n ischemic myocardium (6). Moreover, myocardial isch-
mia frequently is experienced in repeated bouts, which will
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here are currently debates on whether stem cells injected
xogenously are engrafted to become new myocytes or if
hey act as a paracrine cells, secreting cardioprotective
roteins. In either case, the protection of the transplanted
SCs with a gene modification, such as the hypoxic gene
roposed here, will enhance survival, which will lead to
mprovement in cardiac function after transplantation of
SCs into infarct heart. Unknown numbers of newly
egenerated cells may die by apoptosis during tissue remod-
ling and morphogenesis (20). Therapeutic application of
ene-modified MSCs might require additional gene inser-
ions with the ability to protect against ischemia in short-
erm and anti-ischemic/reperfusion damage in the long-
erm. Accordingly, these gene modifications would make
he stem cells “vigilant.” Vigilant stem cells would to be
ngineered with antiapoptosis, antisuperoxide, and anti-
nflammatory genes for better survival in ischemic tissue and
igure 5. Effect of hypoxia-inducible hHO-1 treatment on protecting m
ypoxia-induced hHO-1 overexpression reduces MSC apoptosis in vitro b
n situ nick end labeling assay. After hypoxia/reoxygen/hypoxia treatment,
O-1 expression was low in MSCLacZ or MSCs. The increase in human H
B) A down-regulation in a proapoptotic gene Bax level in the cell lysate o
SCs after hypoxia/reoxygen/hypoxia in vitro.ence to enhance the efficiency of cardiac repair. cSeveral strategies aim at increasing cell survival after
rafting. Suzuki et al. (21) reported that heat-shock treat-
ent could improve cell tolerance to hypoxia-reoxygen
nsult in vitro and enhance survival when grafted into the
eart. Exploiting cell growth and death regulatory factors to
nhance the proliferation of viable stem cells or confer
poptosis resistance to donor cells also is used as a potential
ay to improve cell transplant efficiency. Mangi et al (22)
emonstrated that a direct intramuscular injection of 5 
06 Akt-engineered MSCs improved the function of infarct
at hearts. Akt is a powerful survival signal in many systems
23). However, the overall application of constitutively
ctive Akt gene may increase the risk of tumorigenesis (24).
ang et al. (25) reported that HO-1 overexpression can
rolong small-for-size allograft survival in liver by its
nti-inflammatory action. Our study shows that overexpres-
ion of HO-1 in ischemic myocardium by direct plasmid
njection decreased the number of infiltrating mononuclear
hymal stem cell (MSC) against hypoxia/reoxygen damage in vitro. (A)
terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
of MSCHO-1 expressed human HO-1 in immunostaining whereas human
xpression in MSCHO-1 was accompanied by reduction in the cell apoptosis.
CHO-1 was confirmed by Western blot in comparison with MSCLacZ andesenc
y the
most
O-1 eells, and down-regulated pro-inflammatory cytokines (IL-
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t al. (12) on HO-1.
The possible mechanism of HO-1 action is related to
hosphorylation of p38 mediated by carbon monoxide
athway (26). With our increased understanding of the key
ole of HO-1 in the adaptation and defense against cellular
tress, HO-1 is a good candidate for providing a useful
pproach for cellular protection in ischemic heart through
nti-inflammation and antiapoptosis mechanism (27). We
ave developed a hypoxia regulated vector system (8–10,15)
or modulating tissue, which is based on an oxygen-
ependent degradation domain from the hypoxia inducible
actor-1-alpha. The OST can sense ischemia and switch on
cardioprotective gene (8–10,28). The present study dem-
nstrates that inserting hypoxia-regulated HO-1 vector
ystem into stem cells enhance their survival in ischemic
earts. The decrease in oxygen activates the hypoxia-
nducible vector system expressing hHO-1 in these vigilant
SCs and improves their survival in cell culture and in vivo
fter engraftment to the ischemic myocardium. Mesenchy-
al stem cells modified in this manner could provide both
igure 6. Detection of inflammatory cytokine by Western blot and inflam
own-regulation of interleukin-1 was detected in heme oxygenase-1 plas
levation of interleukin-1b in LacZ plasmid-treated hearts was found. Data
ehydrogenase and compared by Student t test, *p  0.045 compared wit
n ischemic myocardium. The number of CD45-positive cells was decrea
ndicate the groups of CD45-positive cells.ositive paracrine activity and increased likelihood of sur- Pival to become graft cells for tissue regeneration. The
ectors allow transgene expression in the regenerated tissue
rom graft cells to be regulated in response to a physiological
ignal, such as oxygen and to be switched on or off. The
mplification of gene expression provides high enough levels
o be effective.
We quantified the time course of graft cell survival for
ne week as the process of cell death appeared to be largely
ompleted by seven days after grafting (5). Real-time PCR
ssay in gender-mismatched transplant provides us with an
ccurate and sensitive way to measure MSC engraftment in
ivo. It avoids many biases in counting visible donor cells in
andom field from representative tissue sections (16). It is
orthy to notice that there is a great discrepancy in
eporting of graft cell survival. Some studies reported more
han 90% of donor myoblasts died within first hour after
ransplantation in dystrophic mdx female mice (29) using a
-chromosome–specific probe for blotting, whereas
uller-Ehmsen et al. (17) using real-time PCR and Zhang
t al. (5) using TUNEL apoptosis assay both showed most
ell death occurring one to two days after graft. Real-time
y cell infiltration by CD45 staining in ischemic myocardium. (A) and (B)
treated ischemic myocardium one day after treatment, whereas an obvious
shown as mean SE after normalization with glyseraldehyde-3-phosphate
Z. (C) and (D) Immunohistochemical staining to detect the CD45 cells
n HO-1 plasmid-treated myocardium four days after treatment. Arrowsmator
mid-
were
h LacCR assay of Sry gene suggested that many cells were lost
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eeks (17). The quick loss during the first hour after
mplantation mainly is caused by cell retention in the
yringe dead-space, leakage out of the myocardium, or
ash-out through the vascular system, which can be con-
rolled by improving transplantation method. This discrep-
igure 7. Differentiation of graft mesenchymal stem cell (MSC)HO-1 i
ifferentiation. (A) DAPI-labeled nuclei is shown in blue; (B) muscle mark
mage of (A), (B), and (C) indicating that some graft cells adopt cardiac p
ndicates to host ischemic myocardium. 2: Endothelial cell differentiation.
mage of (E) and (F) indicating some graft cells participate in new microvncy may contribute to differences reported in donor cell sype, animal model, and detection method. In our study, we
ombined real-time PCR with TUNEL apoptosis assay to
rovide reliable analysis. The hypoxia regulated HO-1
ector can express exogenous HO-1 earlier than endoge-
ous HO-1 expression, as early as a half hour after ischemia
15), which has been confirmed by another report using a
emic myocardium at 14 days after transplantation. 1) Cardiac muscle
actin in green; (C) cardiac marker cardiac troponin T in red; (D) Merged
type. Arrows point to the graft cell express cardiac mark and arrowhead
API-labeled nuclear; (F) endothelial marker CD31 in green; (G) Merged
formation.n isch
er -
heno
(E) Dimilar system (15,30). Overexpression of HO-1 in early
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ion of graft cell survival.
Graft MSCs require vasculature to provide blood
upply for their survival. It has been demonstrated that
mplanted MSCs can differentiate into endothelial phe-
otype and enhance vascular density as early as day 5 after
mplantation in rat myocardial infarction model (31,32).
his short time window enables the use of plasmid
ectors, which last only 10 to 14 days. Nonviral vectors
re safe and efficient in protecting graft MSCs from
hort-term ischemic damage, which plays a critical role in
raft stem cell death. In additional, hypoxia regulated
O-1 modification did not suppress the differentiation
otential of engrafted MSCs. Our study shows cardiac
uscle differentiation and endothelial cell differentiation of
SCHO-1 in ischemic myocardium. However, the mechanism
f generating new myocytes and endothelial cells by MSCs is
ot clear, which may either from fusion or transdifferentiation
6,33), even at very lower frequency. More recently, we (34)
nd other groups (33) reported that graft stem cells can secrete
everal important survival factors, such as vascular endothelial
igure 8. Quantifying graft male mesenchymal stem cells (MSCs) in th
eal-time amplification plot showing change in normalized reporter dye
erially diluted male MSC genomic DNA. (B) Standard curve generated f
f male MSCs. (C) Time course of graft MSC survival (%). The survival fo
ays; however, the survival for MSCLacZ decreased from 21% to 3.6% forrowth factor, stromal cell-derived factor, basic fibroblast Mrowth factor, hepatocyte growth factor, and insulin-like
rowth factor, which could protect or salvage endangered
schemic myocardium (35). This paracrine effect may be as
mportant as the differentiation potential of stem cells for
unctional improvement.
Acute MI will cause severe ischemia, followed by an
nflammation response, which significantly reduces the
rafted cell survival rate. In this study, the rationale for
hoosing the acute phase of myocardial ischemia as the time
or stem cell transplantation is based on following facts: 1)
he paracrine action from graft stem cells can salvage
schemic myocardium at early phase, and 2) clinical appli-
ation of stem-cell therapy currently exists in most large
eart hospitals as a supplemental treatment to angioplasty
atients with acute MI (36,37). Therefore, protecting graft
ells from acute death in ischemic myocardium is important
or clinical applications. However, the hypoxia-sensitive
ector system only can be activated in an ischemic environ-
ent. Thus, a later treatment would not activate HO-1 and
xert cardiac protection because as collateral circulation is
ebuilt, the myocardial ischemia can be partial released.
ale ischemic myocardium by real-time polymerase chain reaction. (A)
scence (Rn) versus number of amplification cycles in sample containing
ata in (a) showing relationship between threshold cycle (Ct) and number
HO-1 was approximately 68% at 4 h and further decreased to 18% at seven
time period.e fem
fluore
rom doreover, a later application of the vector would produce a
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schemic myocardium.
onclusions. We have demonstrated that a hypoxia-
nducible HO-1 plasmid modification of MSCs protects en-
rafted MSCs from apoptosis and inflammatory injury by the
verexpression of HO-1 in ischemic myocardium. As a treat-
ent, the transplantation of gene modified MSCs is associated
ith the improvement of LV function and ameliorate LV
emodeling. Hypoxia-inducible HO-1 vector modification
ould be an effective graft cell death-prevention strategy. This
vidence is the first using physiologically inducible expression
f therapeutic genes for improving survival of graft stem cells in
schemic myocardium.
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